Anti-elastolytic activity of a honeybee (Apis cerana) chymotrypsin inhibitor.

Biochem Biophys Res Commun

College of Natural Resources and Life Science, Dong-A University, Busan 604-714, Republic of Korea.

Published: January 2013

The honeybee is an important insect species in global ecology, agriculture, and alternative medicine. While chymotrypsin and trypsin inhibitors from bees show activity against cathepsin G and plasmin, respectively, no anti-elastolytic role for these inhibitors has been elucidated. In this study, we identified an Asiatic honeybee (Apis cerana) chymotrypsin inhibitor (AcCI), which was shown to also act as an elastase inhibitor. AcCI was found to consist of a 65-amino acid mature peptide that displays ten cysteine residues. When expressed in baculovirus-infected insect cells, recombinant AcCI demonstrated inhibitory activity against chymotrypsin (K(i) 11.27 nM), but not trypsin, defining a role for AcCI as a honeybee-derived chymotrypsin inhibitor. Additionally, AcCI showed no detectable inhibitory effects on factor Xa, thrombin, plasmin, or tissue plasminogen activator; however, AcCI inhibited human neutrophil elastase (K(i) 61.05 nM), indicating that it acts as an anti-elastolytic factor. These findings constitute molecular evidence that AcCI acts as a chymotrypsin/elastase inhibitor.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2012.11.056DOI Listing

Publication Analysis

Top Keywords

chymotrypsin inhibitor
12
honeybee apis
8
apis cerana
8
cerana chymotrypsin
8
inhibitor acci
8
acci
7
chymotrypsin
5
inhibitor
5
anti-elastolytic activity
4
activity honeybee
4

Similar Publications

Background: Proteasomes degrade intracellular proteins. Different proteasome forms were identified. Proteasome inhibitors are used in cancer therapy, and novel drugs directed to specific proteasome forms are developed.

View Article and Find Full Text PDF

Replacement of a single residue changes the primary specificity of thrombin.

Fertil Steril

January 2025

Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO 63104 USA. Electronic address:

Background: Thrombin prefers substrates carrying Arg at the site of cleavage (P1) because of the presence of D189 in the primary specificity (S1) pocket but can also cleave substrates carrying Phe at P1. The structural basis of this property is unknown.

Objective: Solve the X-ray structure of thrombin bound to a ligand carrying Phe at P1 and investigate the effects of replacing D189.

View Article and Find Full Text PDF

Replacement of a single residue changes the primary specificity of thrombin.

J Thromb Haemost

January 2025

Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO 63104 USA. Electronic address:

Background: Thrombin prefers substrates carrying Arg at the site of cleavage (P1) because of the presence of D189 in the primary specificity (S1) pocket but can also cleave substrates carrying Phe at P1. The structural basis of this property is unknown.

Objective: Solve the X-ray structure of thrombin bound to a ligand carrying Phe at P1 and investigate the effects of replacing D189.

View Article and Find Full Text PDF
Article Synopsis
  • The 3-chymotrypsin-like protease (3CL-PR) of SARS-CoV-2 is essential for virus replication and is targeted by the COVID-19 drug Paxlovid, making it important for understanding its catalytic behavior.
  • Research indicates that the activity of 3CL-PR is pH-dependent, with specific acidic and basic groups necessary for optimal enzymatic function, suggesting a neutral catalytic dyad involving cysteine and histidine.
  • Kinetic studies reveal faster rates in certain conditions, highlighting the influence of the active form of the enzyme, and a full catalytic mechanism for 3CL-PR is proposed based on these findings.
View Article and Find Full Text PDF

This study evaluated the safety and pharmacokinetics (PK) of a single dose of leritrelvir, a novel inhibitor of 3-chymotrypsin-like cysteine protease (3CLpro), in patients with hepatic impairment versus healthy participants with normal hepatic function. Eight participants with mild (Child-Pugh A) hepatic impairment, eight with moderate (Child-Pugh B) hepatic impairment, and eight healthy matched control participants were enrolled in this open-label, parallel clinical trial. After administration of leritrelvir of 400 mg, PK parameters were calculated and compared across groups.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!